Location of Repository

Unique versus redundant functions of IL-1α and IL-1β in the tumor microenvironment

By Elena eVoronov, Shahar eDotan, Yakov eKrelin, Xiaoping eSong, Moshe eElkabets, Yaron eCarmi, Peleg eRider, Idan eCohen, Marianna eRomzova, Irena eKaplanov and Ron Nathan Apte

Abstract

Interleukin-1 (IL-1) is a major alarm upstream pro-inflammatory cytokine that also affects immunity and hematopoiesis by inducing cytokine cascades. In the tumor arena, IL-1 is produced by malignant or microenvironment cells. As a pleiotropic cytokine, IL-1 is involved in tumorigenesis and tumor invasiveness, but also in the control of anti-tumor immunity. IL-1α and IL-1β are the major agonists of IL-1, while IL-1Ra is a physiological inhibitor of pre-formed IL-1. In their secreted form, IL-1α and IL-1β bind to the same receptors and induce the same biological functions, but IL-1α and IL-1β differ in their compartmentalization within the producing cell or the microenvironment. IL-1β is only active in its processed secreted form and mediates inflammation, which promotes carcinogenesis, tumor invasiveness and immunosuppression, whereas IL-1α is mainly cell-associated and in the tumor contest, when expressed on the cell membrane, it stimulates anti-tumor cell immunity manifested by tumor regression. It the tumor milieu, extracellular level of IL-1α is usually low and do not stimulate broad inflammation that promotes progression. Immunosuppression induced by IL-1β in the tumor microenvironment, mainly through MDSC induction, usually inhibits or masks anti-tumor cell immunity induced by cell-associated IL-1α. However, in different tumor systems, redundant or unique patterns of IL-1α and IL-1β expression and function have been observed. Recent breakthroughs in inflammasome biology and IL-1β processing/secretion have spurred the development of novel anti-IL-1 agents, which are being used in clinical trials in patients with diverse inflammatory diseases. Better understanding of the integrative role of IL-1α and IL-1β in distinct malignancies, will enable the application of novel IL-1 modulation approaches at the bedside, in cancer patients with minimal residual disease (MRD), as an adjunct to conventional approaches to reduce the tumor burden

Topics: Immunotherapy, IL-1, Carcinogenesis, anti-tumor immunity, Immunogenicity, tumor invasiveness, Immunologic diseases. Allergy, RC581-607
Publisher: Frontiers Media S.A.
Year: 2013
DOI identifier: 10.3389/fimmu.2013.00177
OAI identifier: oai:doaj.org/article:cffc21fd7aa44e3d8906394c9d33ca59
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1664-3224 (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/cffc2... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.